TOKYO and XIAMEN, March 27, 2025 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that they have submitted a partial change application to the MHLW (Ministry of Health, Labour and Welfare) for the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) as a companion diagnostic (CDx) for Taletrectinib in Japan.
This application is intended for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ROS1 gene fusion. Nippon Kayaku Co., Ltd. (Headquarters: Tokyo) licensed rights to market and distribute Taletrectinib in Japan from Nuvation Bio Inc. and has submitted an application for manufacturing and marketing approval.
If approval is obtained for the additional indication of this product as a primary CDx for Taletrectinib, it is expected to contribute to expanding treatment opportunities for patients with unresectable, advanced / recurrent non-small cell lung cancer (NSCLC) positive for ROS1 gene fusion.
Engineered using cutting-edge PCR technology, the AmoyDx PLC Panel enables the simultaneous detection of activation alterations across 11 critical driver genes (EGFR, ALK, ROS1, KRAS, BRAF, HER2, RET, MET, NTRK1, NTRK2, NTRK3) and identifies actionable mutations in seven of these genes (EGFR, ALK, ROS1, BRAF, MET, KRAS, RET) directly linked to sixteen targeted NSCLC therapies.
“If this application is approved in the future, the AmoyDx PLC Panel can be used as a CDx to identify unresectable, advanced/recurrent NSCLC patients with ROS1 fusion for treatment with Taletrectinib, thereby expanding their therapeutic options.” said Kenji Iwakabe, President and Chief Executive Officer of Riken Genesis, Li-Mou Zheng, Ph.D., Founder and Chairman of AmoyDx and Wenn Sun, Ph.D., Founder and President of PREMIA.
About AmoyDx PLC Panel:
About Riken Genesis Co., Ltd.
RIKEN GENESIS, founded in October 2007, provides lab-assay services as well as products for genetic testing based on cutting-edge gene analysis technologies and bioinformatics, and has experience in the field of personalized medicine. The company provides highly reliable tests based on international quality standards, as demonstrated by its CLIA certification, being the first organization in Japan to meet this U.S. quality control standard for clinical laboratories. For more information, please visit www.rikengenesis.jp.
About Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685)
AmoyDx is at the forefront of championing molecular diagnostics for cancer, committed to enhancing patient outcomes worldwide through innovative diagnostic solutions and breaking barriers for global precision oncology adoption. The company is recognized for its excellence in precision medicine, driving advancements in cancer diagnosis through its extensive collaboration with pharmaceutical companies. For more information, please visit www.amoydiagnostics.com, or follow us at LinkedIn, and X.
About Precision Medicine Asia (PREMIA)
PREMIA offer an integrated platform for the development of innovative oncology therapies and diagnostics in Asia, the fastest growing market for the pharmaceutical industry. PREMIA also manages a clinical-genomic lung cancer registry, the largest in the region, which includes more than 20,000 patients and allows an efficient patient identification process for clinical trial enrollment through participation by more than 200 hospitals in Japan, Taiwan, Malaysia and Thailand. For more information, please visit www.premia-inc.com.
For media inquiries, please contact:
Tatsuro Saito
General Manager, Marketing department
Tel: +81-3-5759-6042
info2@rikengenesis.jp
Robson Ee
Senior Director, International Business.
Info@amoydx.com
Vivian Liu
Director, Corporate Operations
Tel: 852-3978-2288
vliu@premia-inc.com
This application is intended for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ROS1 gene fusion. Nippon Kayaku Co., Ltd. (Headquarters: Tokyo) licensed rights to market and distribute Taletrectinib in Japan from Nuvation Bio Inc. and has submitted an application for manufacturing and marketing approval.
If approval is obtained for the additional indication of this product as a primary CDx for Taletrectinib, it is expected to contribute to expanding treatment opportunities for patients with unresectable, advanced / recurrent non-small cell lung cancer (NSCLC) positive for ROS1 gene fusion.
Engineered using cutting-edge PCR technology, the AmoyDx PLC Panel enables the simultaneous detection of activation alterations across 11 critical driver genes (EGFR, ALK, ROS1, KRAS, BRAF, HER2, RET, MET, NTRK1, NTRK2, NTRK3) and identifies actionable mutations in seven of these genes (EGFR, ALK, ROS1, BRAF, MET, KRAS, RET) directly linked to sixteen targeted NSCLC therapies.
“If this application is approved in the future, the AmoyDx PLC Panel can be used as a CDx to identify unresectable, advanced/recurrent NSCLC patients with ROS1 fusion for treatment with Taletrectinib, thereby expanding their therapeutic options.” said Kenji Iwakabe, President and Chief Executive Officer of Riken Genesis, Li-Mou Zheng, Ph.D., Founder and Chairman of AmoyDx and Wenn Sun, Ph.D., Founder and President of PREMIA.
About AmoyDx PLC Panel:
| (1) Product name | AmoyDx® Pan Lung Cancer PCR Panel |
| (2) Approval No. | 30300EZX00069000 |
| (3) Purpose of use | Detection of EGFR gene mutations, ALK fusion genes, ROS1 fusion genes, BRAF gene mutations, METex14 skipping mutations, KRAS gene mutations and RET fusion genes in nucleic acids extracted from cancer tissue. Used as an adjunct to determine the indications of the following sixteen antineoplastic agents for patients with NSCLC. ・EGFR gene mutation Gefitinib, Erlotinib hydrochloride, Afatinib maleate and Osimertinib mesylate ・ALK fusion genes Crizotinib, Alectinib hydrochloride and Brigatinib ・ROS1 fusion genes Crizotinib, Entrectinib and Repotrectinib ・BRAF V600E mutation Combined administration of Dabrafenib mesylate and Trametinib dimethyl sulfoxide ・MET exon 14 skipping mutations Tepotinib hydrochloride hydrate,Capmatinib hydrochloride hydrate and Gumarontinib hydrate ・KRAS G12C mutation Sotorasib ・RET fusion gene Selpercatinib |
| (4) Testing method | Real-time PCR |
| (5) Sample | FFPE tissue and fresh frozen tissue in which the presence of tumor cells was confirmed |
| (6) Package size | 12 tests / kit |
| (7) Marketing Authorization Holder | Riken Genesis Co., Ltd. |
| (8) Manufacturer | Amoy Diagnostics Co., Ltd. |
About Riken Genesis Co., Ltd.
RIKEN GENESIS, founded in October 2007, provides lab-assay services as well as products for genetic testing based on cutting-edge gene analysis technologies and bioinformatics, and has experience in the field of personalized medicine. The company provides highly reliable tests based on international quality standards, as demonstrated by its CLIA certification, being the first organization in Japan to meet this U.S. quality control standard for clinical laboratories. For more information, please visit www.rikengenesis.jp.
About Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685)
AmoyDx is at the forefront of championing molecular diagnostics for cancer, committed to enhancing patient outcomes worldwide through innovative diagnostic solutions and breaking barriers for global precision oncology adoption. The company is recognized for its excellence in precision medicine, driving advancements in cancer diagnosis through its extensive collaboration with pharmaceutical companies. For more information, please visit www.amoydiagnostics.com, or follow us at LinkedIn, and X.
About Precision Medicine Asia (PREMIA)
PREMIA offer an integrated platform for the development of innovative oncology therapies and diagnostics in Asia, the fastest growing market for the pharmaceutical industry. PREMIA also manages a clinical-genomic lung cancer registry, the largest in the region, which includes more than 20,000 patients and allows an efficient patient identification process for clinical trial enrollment through participation by more than 200 hospitals in Japan, Taiwan, Malaysia and Thailand. For more information, please visit www.premia-inc.com.
For media inquiries, please contact:
Tatsuro Saito
General Manager, Marketing department
Tel: +81-3-5759-6042
info2@rikengenesis.jp
Robson Ee
Senior Director, International Business.
Info@amoydx.com
Vivian Liu
Director, Corporate Operations
Tel: 852-3978-2288
vliu@premia-inc.com
AmoyDx® PD-L1 (E1L3N) Assay Expands Companion Diagnostic Indication to Gastroesophageal Adenocarcinoma in China
Next
Subscribe
to our
newsletter